Boehringer Ingelheim Animal Health has appointed Dr David Strachan as head of its avian and swine business unit, a move which reflects a growing awareness among both avian and swine customers of the impact of individual diseases on production.
Having worked for Boehringer Ingelheim’s swine division for the past 11 years, where he specialised on infectious disease surveillance and control, Dr Strachan’s newly combined avian and swine role builds on Boehringer Ingelheim’s acquisition of Merial Animal Health which was completed just over a year ago.
“There is growing awareness amongst customers, in both the avian and swine sectors, of the costs of individual diseases in terms of their effect on production,” said Dr Strachan (pictured above).
“Subsequently, there is an increasing focus on the return on investment of various intervention measures, especially in relation to the reduction of antibiotic use. The team at Boehringer Ingelheim is well placed to help vets and producers find practical solutions in this area.
“I want to build on the success of Boehringer Ingelheim and Merial’s enviable heritage in the global avian and swine sectors by developing the individual departments’ reputations, ensuring that the combined business remains a trusted partner in providing solutions for disease control.”
Prior to joining Boehringer Ingelheim, he gained a BSc at Glasgow University, followed by a PhD in immunological research. Further studies at The London School of Hygiene and Tropical Medicine and Cambridge University were then followed by 10 years with the SAC Veterinary Investigation Service in Aberdeen.
